Safety and Efficacy of Fluticasone and Beclomethasone in Moderate to Severe Asthma

There are still some concerns about the safety of high doses of inhaled glucocorticosteroids (ICS). We compared the safety and efficacy of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) in 306 patients with moderate to severe asthma in a double-blind, multicenter, cross-over study of 12 mo duration. During the 1-mo run-in period, bronchodilators were replaced by salmeterol 50 μ g twice daily, increasing morning peak expiratory flow rate (PEFR) by 28 L/min (p < 0.001) and FEV1 by 6.2% predicted (p < 0.001). At randomization the current ICS was replaced by 500 μ g BDP or 250 μ g FP in accordance with previously taken 500 μ g BDP or 400 μ g budesonide (BUD). No significant differences between the two treatments regarding morning plasma cortisol, urinary excretion of calcium and hydroxyproline, FEV1, and PEFR were observed at any time point during the study. Osteocalcin and bone mineral density (BMD) were improved over baseline in the FP group, resulting in higher serum osteocalcin levels (...

[1]  D. Chappard,et al.  Altered trabecular architecture induced by Corticosteroids: A Bone Histomorphometric Study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[3]  G. Bootsma,et al.  Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. , 1996, American journal of respiratory and critical care medicine.

[4]  R. Eastell,et al.  Comparison of rates of bone loss from the spine measured using two manufacturers' densitometers , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  M. Johnson,et al.  Fluticasone propionate--an update on preclinical and clinical experience. , 1995, Respiratory medicine.

[6]  Klaus Engelke,et al.  Universal standardization for dual X‐ray absorptiometry: Patient and phantom cross‐calibration results , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Jacques P. Brown,et al.  Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. , 1994, The Journal of allergy and clinical immunology.

[8]  M. Nieminen,et al.  Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. , 1994, Bone.

[9]  C. Rosen,et al.  Glucocorticoids and osteoporosis. , 1994, Endocrinology and metabolism clinics of North America.

[10]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[11]  M. Ip,et al.  Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. , 1994, Chest.

[12]  P. Leblanc,et al.  A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma , 1994, Allergy.

[13]  J. Hébert,et al.  Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler , 1993 .

[14]  L. Fabbri,et al.  Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. , 1993, Thorax.

[15]  G. Marone,et al.  A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. , 1993, The European respiratory journal.

[16]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[17]  P. Autio,et al.  Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen , 1992, The British journal of dermatology.

[18]  M. Hyland,et al.  The Living with Asthma Questionnaire. , 1991, Respiratory medicine.

[19]  P. Geusens,et al.  Locomotor side-effects of corticosteroids. , 1991, Bailliere's clinical rheumatology.

[20]  J. Eisman,et al.  Corticosteroid effects on proximal femur bone loss , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  S. Harding.  The human pharmacology of fluticasone propionate. , 1990, Respiratory medicine.

[22]  A. Adinoff,et al.  Steroid-induced fractures and bone loss in patients with asthma. , 1983, The New England journal of medicine.

[23]  J. Poloniecki,et al.  The Two Period Cross Over Trial , 1982 .

[24]  M. Hills,et al.  The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.